Alendronate therapy in cyclosporine-induced alveolar bone loss in rats

Journal of Periodontal Research

Volumn 42, Issue 5, 2007, Pages 466-473

  Spolidorio, L C ^a   Marcantonio Jr , E ^a   Spolidorio, D M P ^a   Nassar, C A ^a   Nassar, P O ^a   Marcantonio, R A ^a   Rossa Jr , C ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Alendronate; Alveolar bone loss; Biochemical markers of bone turnover; Cyclosporine

Indexed keywords

ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; CALCIUM; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; ISOENZYME; OSTEOCALCIN; TARTRATE-RESISTANT ACID PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BLOOD; BONE DENSITY; CELL COUNT; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; JAW; MALE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; RANDOMIZATION; RAT; WISTAR RAT;

ACID PHOSPHATASE; ALENDRONATE; ALKALINE PHOSPHATASE; ALVEOLAR BONE LOSS; ALVEOLAR PROCESS; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CELL COUNT; CYCLOSPORINE; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; ISOENZYMES; MALE; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 34547762881     PISSN: 00223484     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2007.00970.x     Document Type: Article

References (73)

1. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993 45 : 953 1040.
2. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) 1 in organ transplantation. Drugs 2001 61 : 1957 2016.
3. Marcen R, Cabarello C, Pascual J et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. Transplantation 2006 81 : 826 831.
4. Spolidorio LC, Spolidorio DM, Massucato EM, Neppelenbroek KH, Campanha NH, Sanches MH. Oral health in renal transplant recipients administered cyclosporin A or tacrolimus. Oral Dis 2006 12 : 309 314.
5. Spolidorio LC, Spolidorio DM, Holzhausen M. Effects of long-term cyclosporin therapy on the periodontium of rats. J Periodont Res 2004 39 : 257 262.
6. Epstein S, Shane E, Bilezikian JP. Organ transplantation and osteoporosis. Curr Opin Rheumatol 1995 7 : 255 261.
7. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 2003 14 : 617 630.
8. Duarte PM, Nogueira Filho GR, Sallum EA, de Toledo S, Sallum AW, Nociti FH Jr. The effect of an immunosuppressive therapy and its withdrawal on bone healing around titanium implants. A histometric study in rabbits. J Periodontol 2001 72 : 1391 1397.
9. Silva HC, Coletta RD, Jorge J, Bolzani G, de Almeida OP, Graner E. The effect of cyclosporin A on the activity of matrix metalloproteinases during the healing of rat molar extraction wounds. Arch Oral Biol 2001 46 : 875 879.
10. Gau CH, Hsieh YD, Shen EC, Lee S, Chiang CY, Fu E. Healing following tooth extraction in cyclosporine-fed rats. Int J Oral Maxillofac Surg 2005 34 : 782 788.
11. Reginster JY, Sarlet N. The treatment of severe postmenopausal osteoporosis: a review of current and emerging therapeutic options. Treat Endocrinol 2006 5 : 15 23.
12. Hochberg MC, Rizzoli R. Long-term experience with alendronate in the treatment of osteoporosis. Expert Opin Pharmacother 2006 7 : 1201 1210.
13. Madenci E, Yilmaz K, Yihmaz M, Coskun Y. Alendronate treatment in osteogenesis imperfecta. J Clin Rheumatol 2006 12 : 53 56.
14. Sen C et al. Effects of calcitonin and alendronate on distraction osteogenesis. Int Orthop 2006 30 : 272 277.
15. Liel Y. Paget's disease and bisphosphonates. N Engl J Med 2005 353 : 2616 2618 author reply 2616-8.
16. Newman ED, Matzko CK, Olenginski TP et al. Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 2006 17 : 1706.
17. Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 2006 17 : 1268 1274.
18. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med 2006 119 : S3 S11.
19. Delibasi T, Altundag K, Kanlioglu Y. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors. J Oral Maxillofac Surg 2006 64 : 995 996.
20. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006 102 : 433 441.
21. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park) 2006 20 : 1053 1062 discussion 1065 1066.
22. Scully C, Madrid C, Bagan J. Dental endosseous implants in patients on bisphosphonate therapy. Implant Dent 2006 15 : 212 218.
23. Wassef R, Cohen Z, Langer B. Pharmacokinetic profiles of cyclosporine in rats. Influence of route of administration and dosage. Transplantation 1985 40 : 489 493.
24. Nassar CA, Nassar PO, Abi Rached RS, Holzhausen M, Marcantonio E Jr., Spolidorio LC. Effect of cyclosporin A on alveolar bone homeostasis in a rat periodontitis model. J Periodont Res 2004 39 : 143 148.
25. Bikle DD, Morey-Holton ER, Doty SB, Currier PA, Tanner SJ, Halloran BP. Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage. J Bone Miner Res 1994 9 : 1777 1787.
26. Camacho NP, Raggio CL, Doty SB et al. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 2001 69 : 94 101.
27. Azuma Y, Oue Y, Kanatani H, Ohta T, Kiyoki M, Komoriya K. Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats. J Pharmacol Exp Ther 1998 286 : 128 135.
28. Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Bone 2003 32 : 268 274.
29. Spadaro JA, Damron TA, Horton JA, Margulies BS, Murray GM, Clemente DA, Strauss JA. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge. J Orthop Res 2006 24 : 936 944.
30. Wada C et al. High-turnover osteoporosis is induced by cyclosporin A in rats. J Bone Miner Metab 2006 24 : 199 205.
31. Ogawa K et al. Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats. J Bone Miner Metab 2005 23 : 351 358.
32. Parfitt AM. Bone histomorphometry: standardization of nomenclature, symbols and units (summary of proposed system). Bone 1988 9 : 67 69.
33. Cunningham J. Posttransplantation bone disease. Transplantation 2005 79 : 629 634.
34. Epstein S et al. Transforming growth factor-beta administration modifies cyclosporine A-induced bone loss. Bone 2001 28 : 583 588.
35. Ugur A, Guvener N, Isiklar I, Turan M, Erdal R, Haberal M. Osteoporosis after renal transplantation: single center experience. Transplantation 2001 71 : 645 649.
36. Grotz W, Wanner C, Rother E, Schollmeyer P. Clinical course of patients with antineutrophil cytoplasm antibody positive vasculitis after kidney transplantation. Nephron 1995 69 : 234 236.
37. Moreno M, Manzanares C, Castellano F et al. Monitoring of tacrolimus as rescue therapy in pediatric liver transplantation. Ther Drug Monit 1998 20 : 376 379.
38. Loinaz C, Marquez E, Gomez R et al. Clinical features of 32 patients after 8 years of a liver transplant. Transplant Proc 1999 31 : 2475 2476.
39. Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 1996 28 : 105 114.
40. Kataoka M et al. Cyclosporin A decreases the degradation of type I collagen in rat gingival overgrowth. J Cell Physiol 2000 182 : 351 358.
41. Cunningham J. Posttransplantation bone disease. Transplantation 2005 79 : 629 634.
42. Yao KL, Todescan R Jr., Sodek J. Temporal changes in matrix protein synthesis and mRNA expression during mineralized tissue formation by adult rat bone marrow cells in culture. J Bone Miner Res 1994 9 : 231 240.
43. Ikedo D et al. Stimulatory effects of phenytoin on osteoblastic differentiation of fetal rat calvaria cells in culture. Bone 1999 25 : 653 660.
44. Igarashi Y, Lee MY, Matsuzaki S. Acid phosphatases as markers of bone metabolism. J Chromatogr B Analyt Technol Biomed Life Sci 2002 781 : 345 358.
45. Mason J. Renal side-effects of cyclosporin A. Br J Dermatol 1990 122 : 71 77.
46. Ryffel B. Cyclosporin. Toxicology - experimental studies. Prog Allergy 1986 38 : 181 197.
47. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988 123 : 2571 2577.
48. Rucinski B, Liu CC, Epstein S. Utilization of cyclosporine H to elucidate the possible mechanisms of cyclosporine A-induced osteopenia in the rat. Metabolism 1994 43 : 1114 1118.
49. Buchinsky FJ, Ma Y, Mann GN et al. Bone mineral metabolism in T lymphocyte-deficient and -replete strains of rat. J Bone Miner Res 1995 10 : 1556 1565.
50. Chowdhury MH, Shen V, Dempster DW. Effects of cyclosporine A on chick osteoclasts in vitro. Calcif Tissue Int 1991 49 : 275 279.
51. McCauley LK, Rosol TJ, Capen CC. Effects of cyclosporin A on rat osteoblasts (ROS 17/2.8 cells) in vitro. Calcif Tissue Int 1992 51 : 291 297.
52. Sass DA, Bownam AR, Yuan Z, Ma Y, Jee WS, Epstein S. Alendronate prevents cyclosporin A-induced osteopenia in the rat. Bone 1997 21 : 65 70.
53. Altundal H, Gursoy B. The influence of alendronate on bone formation after autogenous free bone grafting in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005 99 : 285 291.
54. Ogawa K et al. Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats. J Bone Miner Metab 2005 23 : 351 358.
55. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006 21 : 349 353.
56. D'Aoust P, McCulloch CA, Tenenbaum HC, Lekic PC. Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell Tissue Res 2000 302 : 353 363.
57. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996 137 : 2324 2333.
58. Giuliani N, Pedrazzpni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998 22 : 455 461.
59. Thompson K et al. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006 69 : 1624 1632.
60. Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996 19 : 281 290.
61. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999 56 : 131 140.
62. van Beek E, Pieterman F, Cohen L, Lowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999 264 : 108 111.
63. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000 373 : 231 241.
64. Dunford JE, Thompson K, Coxon FP et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001 296 : 235 242.
65. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998 13 : 581 589.
66. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003 9 : 2643 2658.
67. Auriola S, Frith J, Rogers MJ, Koivuniemi A, Monkkonen J. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 1997 704 : 187 195.
68. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001 44 : 2201 2210.
69. Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990 5 : 31 40.
70. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996 101 : 488 501.
71. Chavassieux PM, Arlot ME, Roux JP et al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000 15 : 754 762.
72. Devogelaer JP, Broll H, Correa-Rotter R et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996 18 : 141 150.
73. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 1996 18 : 621 627.